---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-252557"
form_type: "8-K"
ticker: "MDLN"
cik: "0002046386"
company_name: "Medline Inc."
filed_at: "2026-06-02T12:06:32+00:00"
generated_at: "2026-06-02T12:10:45.137846+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Medline issues $2.0B senior secured notes & refinances $2.75B term loan; secondary offering of 72.6M shares at $37

## Summary
- Issued $1.25B of 5.000% senior secured notes due 2031 and $750M of 5.250% senior secured notes due 2033.
- New $2.75B term loan facility (SOFR+1.50% or Base+0.50%) due 2033 refinances existing term loans.
- Proceeds used to repay $724M of 2030 term loan and $500M of 6.250% notes due 2029.
- Selling stockholders (Blackstone, Hellman & Friedman, ADIA) sold 72,554,594 shares at $37.00 per share.
- Underwriters have a 30-day option to purchase up to an additional 10,883,189 shares.

## SEC filing metadata
- accession: 0001193125-26-252557
- form_type: 8-K
- ticker: MDLN
- cik: 0002046386
- company_name: Medline Inc.
- filed_at: 2026-06-02T12:06:32+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 2.03, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2046386/000119312526252557/0001193125-26-252557-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2046386/000119312526252557/d50280d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-252557
- JSON: https://secwatch.observer/filing/0001193125-26-252557.json
- Plain text: https://secwatch.observer/filing/0001193125-26-252557.txt

## Source-grounded claims
- claim_id: bb61f945f413f532155069ee720eb4e4f7bdd98d
  claim: Medline Inc. entered into 2033 Refinancing Term Loan Facility with Not specified valued at Refinanced existing senior secured dollar-denominated term loan facility due 2030 with a new senior (effective 2026-05-28).
  evidence_excerpt: Concurrently with the Notes offering, the Issuer refinanced its existing senior secured dollar-denominated term loan facility due 2030 (the “ 2030 Term Loan Facility ”) with a new senior secured dollar-denominated term loan facility in an aggregate principal amount of approximately $2,750.0 million (the “ 2033 Refinancing Term Loan Facility ” and, together with the existing revolving credit facility, the “ Senior Secured Credit Facilities ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/2046386/000119312526252557/0001193125-26-252557-index.htm
- claim_id: cd819fe61fb0bb5a814596f83bbf8f7baf3089ca
  claim: Medline Inc. entered into Indenture for 5.000% Senior Secured Notes due 2031 and 5.250% Senior Secured Notes due 2033 with Wilmington Trust, National Association valued at Issued $1,250.0 million aggregate principal amount of 5.000% senior secured notes due 2031 and $750. (effective 2026-05-28).
  evidence_excerpt: On May 28, 2026, Medline Borrower, LP (the “ Issuer ”) and Medline Co-Issuer, Inc. (the “ Co-Issuer ” and, together with the Issuer, the “ Issuers ”), indirect subsidiaries of Medline Inc. (the “ Company ”), issued $1,250.0 million aggregate principal amount of 5.000% senior secured notes due 2031 (the “ 2031 Notes ”) and $750.0 million aggregate principal amount of 5.250% senior secured notes due 2033 (the “ 2033 Notes ” and, together with the 2031 notes, the “ Notes ”), under an Indenture, dated as of May 28, 2026 (the “ Indenture ”), among the Issuers, Medline Intermediate, LP (“ Holdings ”), the direct parent of the Issuer, the subsidiary guarantors party thereto and Wilmington Trust, National Association, as trustee (in such capacity, the “ Trustee ”), paying agent, transfer agent, registrar and notes collateral agent (in such capacity, the “ Notes Collateral Agent ”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/2046386/000119312526252557/0001193125-26-252557-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.